Mitsubishi Tanabe Pharma America, Inc. (MTPA), a wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corporation's (MTPC) 100% owned US holding company, Mitsubishi Tanabe Pharma Holdings America, Inc, announced on Friday that it has received approval from the United States Food and Drug Administration (FDA) for its RADICAVA ORS (edaravone), the oral form of edaravone, intended to treat amyotrophic lateral sclerosis (ALS).
The company said that the product provides the same efficacy as RADICAVA (edaravone), an FDA-approved intravenous (IV) treatment shown in a pivotal trial to support reducing the loss of physical function in ALS. It is specifically formulated for patients with ALS and provides a flexible administration option (taken orally or via feeding tube) with a small, five mL dose, a portable bottle, an oral dosing syringe and no requirement for patients to refrigerate or reconstitute before taking.
Tulio Bertorini, M.D., professor of Neurology, The University of Tennessee Health Science Center, said, 'ALS is a progressive disease that, due to its heterogenous nature, impacts patients at different rates with varying symptoms. Therefore, it is crucial that patients have treatment and formulation options that accommodate their own unique needs, and RADICAVA ORS provides HCPs who have prescribed their ALS patients edaravone with an alternate delivery option.'
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Illumina's GRAIL divestment plan receives EC approval
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Ondine Biomedical's Steriwave approved for use by HCA UK
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial
Syros receives Fast Track Designation from FDA for tamibarotene in AML
Ligand Pharmaceuticals announces presentation of Captisol-enabled Topiramate Injection data